Disease Overlap, Healthcare Resource Utilization, and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A REVEAL Sub-study
EGPA was associated with substantial HCRU and costs, driven by outpatient and inpatient settings. More overlapping EADs were associated with higher HCRU and costs, highlighting the need for treatment to reduce healthcare expenditure in these patients. Infographic available for this article.
Authors
- Heide A. Stirnadel-Farrant (ORCID: https://orcid.org/0000-0003-0734-0422)
- Justin Kwiatek (ORCID: https://orcid.org/0000-0002-1862-0238)
- Michael Stokes (ORCID: https://orcid.org/0000-0002-1822-6214)
- Rohit Katial (ORCID: https://orcid.org/0000-0002-0627-2467)
- Yong-Jin Kim (ORCID: https://orcid.org/0000-0002-3055-9943)
- Xiao Xu (ORCID: https://orcid.org/0009-0003-5547-1686)
- Christopher Edmonds (ORCID: https://orcid.org/0000-0001-9976-8375)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Cégep de Saint-Laurent (CA)
- AstraZeneca (France) (FR)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Poland) (PL)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1007/s40744-024-00714-w
- Citations
- 1
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- AstraZeneca